XOMA Royalty Corp (NASDAQ: XOMA)

XOMA Corp, also known by its stock symbol XOMA, operates in the biotech industry as a royalty aggregator. The company's primary business activities involve acquiring and licensing intellectual property rights to pharmaceutical companies, which then develop and commercialize products that generate royalties and milestone payments for XOMA. The company's portfolio includes a diverse range of therapeutic candidates, such as sufentanil sublingual tablet (DSUVIA), tovorafenib (DAY101), and cetrelimab (JNJ-6372), among others. These products are being developed by various pharmaceutical companies, including Alora Pharmaceuticals, Day One Biopharmaceuticals, and Janssen Biotech.

XOMA Corp's revenue is generated primarily through royalties and milestone payments associated with its portfolio of therapeutic candidates. The company's portfolio is divided into several segments, including the Royalty Portfolio, Commercial Programs, Pre-Commercial Programs, and Selected Programs. The Royalty Portfolio includes the company's rights to future royalties and milestone payments from various pharmaceutical companies. The Commercial Programs segment includes the company's rights to commercial payments from pharmaceutical companies, such as the sales of IXINITY, which is marketed by Medexus. Pre-Commercial Programs include the company's rights to milestone and royalty payments from pre-commercial programs, such as the development and commercialization of products like DAY101. Finally, Selected Programs include the company's rights to milestone and royalty payments from specific programs, such as Takeda's CFZ533 and Rezolute's RZ358.

XOMA Corp's competitive advantages include its diverse portfolio of intellectual property rights, its ability to acquire and license rights to pharmaceutical companies, and its expertise in the biotech industry. The company's licensees and partners include major pharmaceutical companies, which provides a stable source of revenue. The company's customers include major pharmaceutical companies such as Roche, Takeda, Novartis, and others. These relationships are critical to XOMA Corp's success, as they provide a steady stream of revenue and help to drive the development and commercialization of new products.

The company's primary products and services include a diverse range of therapeutic candidates, such as DSUVIA, DAY101, and cetrelimab. XOMA Corp's business model is dependent on third parties achieving specified development milestones and product sales. The company's portfolio currently includes partner-funded programs from which it could potentially receive royalties or other payments if the programs achieve marketability. A large percentage of the calculated net present value of the portfolio is represented by a limited number of products.

XOMA Corp's intellectual property is important to its business, and its future income streams will depend in part on its partners and licensees' ability to obtain patents and to operate without infringing on the proprietary rights of others. The company holds and has filed applications for a number of patents in the U.S. and internationally to protect its products and technology. However, the patent position of biotechnology companies generally is highly uncertain, and consistent policy regarding the breadth of allowed claims has not emerged from the actions of the U.S. Patent and Trademark Office with respect to biotechnology patents.

Compliance with government regulations is also critical to XOMA Corp's business. The company is subject to regulation by numerous governmental authorities in the U.S. and other countries, and failure to comply with applicable regulatory requirements can result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. The company is also subject to pricing-related regulations, which can impact the sales of its products and the royalties it receives.